NCT01929109View on ClinicalTrials.gov

A Study of LY2409021 in Participants With Different Levels of Kidney Function

PHASE1CompletedINTERVENTIONAL
Enrollment

47

Participants

Timeline

Start Date

August 31, 2013

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Kidney Failure, ChronicRenal Insufficiency, Chronic
Interventions
DRUG

LY2409021

Administered orally

Trial Locations (2)

81241

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Munich

L7 8XP

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Liverpool

All Listed Sponsors
lead

Eli Lilly and Company

INDUSTRY

NCT01929109 - A Study of LY2409021 in Participants With Different Levels of Kidney Function | Biotech Hunter | Biotech Hunter